Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This research study is investigating the safety and effectiveness of using combination of
isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple
myeloma (MM). The study team will use lower doses than is currently standard for these drugs.
Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly
associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide
and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the
treatment of newly diagnosed MM.